"Lisocabtagene maraleucel in relapsed or refractory diffuse large B cel" by Mohamed A. Kharfan-Dabaja, Farah Yassine et al.

Article Title

Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?

Authors

Mohamed A. Kharfan-Dabaja, Division of Hematology–Oncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville, FL, USAFollow
Farah Yassine, Division of Hematology–Oncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Muhamad Alhaj Moustafa, Division of Hematology–Oncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Madiha Iqbal, Division of Hematology–Oncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville, FL, USA
Hemant Murthy, Division of Hematology–Oncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville, FL, USA

Abstract

Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3f activatory domain connected to 4-1BB costimulatory domain. Liso-cel, unlike the other two approved products—axicabtagene ciloleucel and tisagenlecleucel— is manufactured separately from CD4 and CD8 T cells and then administered as a sequential infusion of the two components at equal target doses. The approval of liso-cel was based on the results of Transcend NHL 001, a single-arm, open-label, multicenter, seamless design trial that enrolled 344 patients, of whom 269 received conforming liso-cel. The most common histology was diffuse large B cell lymphoma, not otherwise specified (DLBCL NOS; n = 137, 51%) followed by DLBCL transformed from indolent lymphomas (n = 78, 29%). Encouraging results were reported, yielding an objective response rate across all dose levels of 73% [complete remission (CR) = 53%], with an estimated duration of response at 1 year of 55% for all patients and 65% for those achieving a CR. The estimated 12-month overall survival was 58% for all patients and 86% for those achieving a CR. Cytokine release syndrome and neurological adverse events were reported in 42% and 30%, respectively. This review summarizes the evidence on the safety and effectiveness of liso-cel, resulting in its addition to the current treatment armamentarium of relapsed or refractory large B cell lymphoma.

Recommended Citation

Kharfan-Dabaja, Mohamed A.; Yassine, Farah; Moustafa, Muhamad Alhaj; Iqbal, Madiha; and Murthy, Hemant (2022) "Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?," Hematology/Oncology and Stem Cell Therapy: Vol. 15 : Iss. 4 , Article 1.
Available at: https://doi.org/10.1016/j.hemonc.2021.09.004